Compare AVNS & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNS | LENZ |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.7M | 609.5M |
| IPO Year | N/A | 2021 |
| Metric | AVNS | LENZ |
|---|---|---|
| Price | $15.12 | $13.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $56.25 |
| AVG Volume (30 Days) | 589.0K | ★ 1.1M |
| Earning Date | 02-20-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $699,900,000.00 | $17,500,000.00 |
| Revenue This Year | $3.07 | N/A |
| Revenue Next Year | $2.16 | $194.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.70 | N/A |
| 52 Week Low | $9.30 | $13.58 |
| 52 Week High | $16.80 | $50.40 |
| Indicator | AVNS | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 77.08 | 30.94 |
| Support Level | $12.75 | $14.87 |
| Resistance Level | $14.61 | $21.80 |
| Average True Range (ATR) | 0.47 | 1.33 |
| MACD | 0.16 | -0.33 |
| Stochastic Oscillator | 100.00 | 8.63 |
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.